Concurrent or Sequential Chemoradiotherapy after 3-4 Cycles Induction Chemotherapy for LS-SCLC with Bulky Tumor

This study demonstrated that after the completion of 3-4 cycles of chemotherapy with a remission, concurrent chemoradiotherapy with oral etoposide and cisplatin improved survival compared with sequential chemoradiotherapy in LS-SCLC with bulky tumor. ClinicalTrials.gov Identifier: NCT01745445.

http://www.jcancer.org/v11p4957.htm

Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Jingjing Zhao, Wencheng Zhang, Puchun Er, Xi Chen, Yong Guan, Dong Qian, Jun Wang, Zhiyong Yuan, Lujun Zhao, Ping Wang, Qingsong Pang Tags: Research Paper Source Type: research